Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers.
Rujas, E., Kucharska, I., Tan, Y.Z., Benlekbir, S., Cui, H., Zhao, T., Wasney, G.A., Budylowski, P., Guvenc, F., Newton, J.C., Sicard, T., Semesi, A., Muthuraman, K., Nouanesengsy, A., Aschner, C.B., Prieto, K., Bueler, S.A., Youssef, S., Liao-Chan, S., Glanville, J., Christie-Holmes, N., Mubareka, S., Gray-Owen, S.D., Rubinstein, J.L., Treanor, B., Julien, J.P.(2021) Nat Commun 12: 3661-3661
- PubMed: 34135340 
- DOI: 10.1038/s41467-021-23825-2
- Primary Citation of Related Structures:  
7K9Z - PubMed Abstract: 
SARS-CoV-2, the virus responsible for COVID-19, has caused a global pandemic. Antibodies can be powerful biotherapeutics to fight viral infections. Here, we use the human apoferritin protomer as a modular subunit to drive oligomerization of antibody fragments and transform antibodies targeting SARS-CoV-2 into exceptionally potent neutralizers ...